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Type 2 diabetes mellitus (T2DM) is prevalent in patients undergoing cardiac transplantation. In those without 
diabetes mellitus before transplant, many will develop abnor-
malities of glucose metabolism in the posttransplant period. 
Both preexisting T2DM and posttransplant diabetes mellitus 
(PTDM) are prognostically significant following heart trans-
plant and are associated with increased morbidity and mor-
tality compared with other transplant recipients with normal 
glucose metabolism.1 In the modern era, survival following 
heart transplantation has improved, primarily because of 
improvements in immunosuppressive and anti-infective 
medication availability and tolerability.2 However, the diabe-
togenic effects of these agents have contributed to increased 
rates of PTDM, and the optimal management of diabetes 
mellitus in the posttransplant period remains ill defined, 
particularly with regard to the use of newer oral glucose-
lowering agents such as the sodium glucose cotransporter 2 
(SGLT2) inhibitors.3
Heart Transplantation
Background. Type 2 diabetes mellitus (T2DM) is prevalent in patients undergoing heart transplant, and in those without 
preexisting T2DM, posttransplant diabetes mellitus may develop. Both T2DM and posttransplant diabetes mellitus have 
been associated with increased morbidity and mortality following heart transplantation. Empagliflozin is an effective glucose-
lowering therapy that reduces the incidence of major cardiovascular events in patients with T2DM. The safety and efficacy 
of empagliflozin in transplant patients with diabetes mellitus has yet to be established. Methods. Clinical outcomes were 
retrospectively examined in 22 heart transplant recipients treated with empagliflozin and compared with those of 79 heart 
transplant patients with diabetes mellitus receiving alternative glucose-lowering therapies. Results. Three adverse events 
were recorded in empagliflozin-treated patients, leading to treatment discontinuation in 1. There were no genitourinary infec-
tions. Treatment with empagliflozin for 12 months was associated with reductions in weight, body mass index, glycated 
hemoglobin, and frusemide dose that were not seen in the control group. There were no large changes observed in blood 
pressure (systolic or diastolic) or renal function (serum urea, creatinine, or estimated glomerular filtration rate) after 12 months 
of treatment with empagliflozin or alternative glucose-lowering therapies. Conclusions. Empagliflozin appears safe and 
effective in the management of selected patients with diabetes mellitus following heart transplantation.
(Transplantation Direct 2019;5:e450; doi: 10.1097/TXD.0000000000000885. Published online 25 April, 2019.)
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Empagliflozin is one such SGLT2 inhibitor. It exerts a 
glucose-lowering effect via induction of glycosuria through 
inhibition of SGLT2 channels in the proximal renal tubule.4 
In a large randomized trial of patients with T2DM and 
established cardiovascular disease and/or risk factors, 
empagliflozin was associated with significant reductions in 
major adverse cardiovascular events, hospitalizations for 
heart failure, and all-cause mortality.5 Additional studies 
have reported further benefits with the use of empagliflo-
zin, including reduction in glycated hemoglobin (HbA1c) 
levels, weight, blood pressure, arterial stiffness and vascular 
resistance, albuminuria, visceral adiposity, and plasma urate 
levels.6-8 The primary aim of this study was to investigate 
the safety of empagliflozin in the postheart transplant dia-
betic population with a particular focus on the incidence 
of genitourinary infections in an immunosuppressed patient 
population. Secondary aims of this study were to describe 
long-term effectiveness of empagliflozin in the postheart 
transplant diabetic population with regard to HbA1c, weight, 




One hundred and one consecutive heart transplant recipi-
ents with either T2DM predating transplant or PTDM were 
reviewed in the heart  transplant follow-up clinic between 
January 1, 2015, and August 14, 2017. Results of outcomes 
after at least 3 months of empagliflozin treatment have been 
reported previously by our group.9
Study Design
We conducted a retrospective single-center observational 
study of patients attending the heart transplant clinic at a 
single center. It is routine for heart transplant recipients to 
attend clinic at least biannually, with more frequent visits 
for patients in the first 2 years posttransplantation or among 
those with transplant-related complications. Before trans-
plantation, patients were not routinely screened for diabe-
tes mellitus. However, patients undergo multiple random 
plasma glucose samples before transplantation, which would 
identify most cases of impaired glucose tolerance and overt 
T2DM. Following transplantation, blood glucose levels were 
monitored 4 times daily in hospital, and if they remained 
elevated at the time of discharge, patients were taught to 
self-monitor glucose levels and followed up in a dedicated 
transplant-endocrine clinic. Eligible participants were 
selected using clinic attendance records to confirm heart 
transplant and diabetes mellitus status. T2DM was defined 
in accordance with the American Diabetes Society consensus 
guidelines,10 and PTDM was defined by the diagnostic cri-
teria outlined in the most recent international guidelines.11 
Only patients with follow-up after a minimum period of 12 
months of empagliflozin therapy or other diabetes mellitus 
treatment were included in this analysis. The decision to 
commence empagliflozin was made by the treating endocri-
nologist or cardiologist. Treatment was altered throughout 
the study period as clinically indicated. The study protocol 
was approved by the human research ethics committee at St. 
Vincent’s Hospital, Sydney. The reference number for this 
study is LNR/16/SVH/215.
Data Collection
Data were collected through review of hospital records, 
specialist letters, and internal/external pathology results. 
Demographic data (age, sex, comorbidities, diabetes mellitus 
status, diabetes mellitus duration, and transplant date) were 
confirmed via medical record. Adverse effects that could be 
reasonably attributed to empagliflozin were documented.
Outcome Measures
The primary outcome was the prevalence of adverse effects 
attributable to empagliflozin, with genitourinary infection 
as the key variable of interest. Genitourinary and perineal 
infections were detected clinically in patients presenting 
with symptoms and signs and confirmed microbiologically. 
Routine screening for asymptomatic genitourinary infection 
was not performed. The secondary outcomes compared the 
effect of treatment with empagliflozin at 12 months with that 
of non-empagliflozin-based diabetes mellitus management 
on body weight, BMI, blood pressure, HbA1c, diuretic usage 
(furosemide dose), and renal function.
Statistical Analysis
Continuous variables were expressed as mean ± SD or 
median ± interquartile range. Categorical data were expressed 
as frequencies and percentages of the overall cohort. Wilcoxon 
signed-rank tests were used to compare changes in body 
weight, BMI, systolic and diastolic blood pressures, HbA1c, 
insulin dose, furosemide dose, urea, serum creatinine, and esti-
mated glomerular filtration rate (eGFR) before empagliflozin, 
with subsequent measurements occurring at least 12 months 
following drug initiation. This procedure was repeated for 
patients receiving any other form of diabetes mellitus treat-
ment without empagliflozin. All analyses were performed 
using SPSS software version 24.0 (SPSS Inc., Chicago, IL). All 
reported values are 2-sided with statistical significance defined 
as P < 0.05.
RESULTS
Throughout the study period, 337 heart transplant recipi-
ents attended clinic for routine follow-up. The mean age was 
56.3 ± 14.4 years, with an average time posttransplant of 10.1 
years. The cohort was predominantly male (71%), and T2DM 
or PTDM was present in 101 patients (30%), with an average 
diabetes mellitus duration of 8.2 years. There were 22 patients 
treated with empagliflozin as a component of their diabetes 
mellitus therapy. Empagliflozin use was not randomized, and 
dose was determined by the prescribing physician, with 5 
patients commencing treatment before transplantation. In the 
empagliflozin cohort, 12 patients received 10 mg daily, and 10 
received 25 mg daily. Pretreatment and posttreatment data, 
recorded 12 months after beginning empagliflozin therapy, 
were available for 20 of 22 patients. Twelve-month follow-up 
data were available for 77 of 79 patients treated with non-
empagliflozin-based glucose-lowering treatments. Baseline 
characteristics are presented in Table 1. Groups were similar 
at baseline apart from metformin use, with 68% (15/22) of 
the empagliflozin group coprescribed metformin compared 
with 23% (18/79) in the control group.
Across 384 collective months of empagliflozin treatment in 
22 patients, there were 3 adverse effects potentially attributa-
ble to treatment with empagliflozin. Adverse effects are noted 
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in Table  2. Interestingly, there were no genitourinary tract 
infections documented in the empagliflozin-treated group 
compared with 9 urinary infections in heart transplant recipi-
ents treated using non-empagliflozin-based diabetes mellitus 
medications.
Following 12 months of treatment with empagliflozin, there 
was a significant reduction in median body weight of 2.0 kg 
(P = 0.003; mean reduction 4.7 ± 5.7), and a correspond-
ing median decrease in BMI of 1.3 kg/m2 (P = 0.004; mean 
reduction 1.6 ± 2.0). Weight reduction was concurrent with 
a significant decrease in median furosemide dose (P = 0.02). 
In contrast, the control group did not experience significant 
reductions in weight, BMI, or furosemide dosage. Systolic and 
diastolic blood pressures were not significantly different fol-
lowing 12 months of empagliflozin treatment, which was also 
the case in participants treated with non-empagliflozin-based 
therapies. Glycemic control improved following 12 months of 
treatment with empagliflozin, with a mean reduction in HbA1c 
of 6.6 mmol/mol. Although statistically nonsignificant, glyce-
mic control in non-empagliflozin-treated subjects deteriorated 
at 12 months, with an average HbA1c increase of 3.7 mmol/
mol, yielding a difference of 10.3 mmol/mol. Both empagli-
flozin and control groups experienced nonsignificant changes 
in renal function based on biochemical parameters. Pre- and 
postresults are presented in Table 3 for patients treated with 
empagliflozin and in Table 4 for patients treated with non-
empagliflozin-based diabetes mellitus medications.
DISCUSSION
Diabetes mellitus remains a significant issue in the manage-
ment of patients following cardiac transplantation. As long-
term survival continues to improve, so too will the incidence 
of PTDM. The role of novel antihyperglycemic agents, such 
as SGLT2 inhibitors, remains to be established. Given their 








Age, y; mean ± SD 59.3 ± 11.9 58.0 ± 11.4
Weight, kg; median (IQR) 89.1 (80.0–101.7) 77.1 (69.0–90.5)
BMI, kg/m2; median (IQR) 30.3 (25.6–32.4) 27.2 (24.1–30.7)
Males, n (%) 17 (77) 54 (68)
Time since transplant, y; median (IQR) 5.0 (2.0–12.3) 8.0 (3.0–17.0)
Diabetes mellitus duration, y; median 
(IQR)
8.0 (3.5–14.5) 6.0 (1.5–14.0)
 PTDM, n (%) 9 (40.9) 47 (60)
Comorbidities, n (%)   
 Hypertension 21 (96) 69 (87)
 Chronic kidney disease 20 (91) 68 (86)
 Hypercholesterolemia 21 (96) 74 (94)
Immunosuppressive agent, n (%)   
 Prednisone 10 (46) 38 (48)
 Calcineurin inhibitor 17 (77) 54 (70)
  Tacrolimus 11 (65) 29 (54)
  Cyclosporine 6 (35) 25 (46)
 Everolimus 10 (45) 35 (44)
Diabetes mellitus therapy, n (%)   
 Insulin 9 (41) 43 (54)
 Metformin 15 (68) 18 (23)
 Sulfonylurea 6 (27) 12 (15)
 DPP-4 inhibitor 3 (14) 6 (8)
Furosemide use, n (%) 10 (46) 36 (46)
BMI, body mass index; DDP-4, dipeptidyl peptidase 4; IQR, interquartile range; PTDM, post-
transplant diabetes mellitus.
TABLE 2.
Adverse effects recorded in patients treated with empagli-
flozin over 12 mo
Adverse effect




Cessation of  
empagliflozin
Exacerbation of urinary 
symptoms
1 No No
Dizziness 1 No No
Acute kidney injurya 1 No Yes
Genitourinary infection 0 NA NA
aBaseline creatinine: 121-239 μmol/L; eGFR: 42.0-18.0 mL/min.
eGFR, estimated glomerular filtration rate NA, not applicable.
TABLE 3.
Metabolic and hemodynamic outcomes in heart transplant 
recipients with diabetes mellitus before and after 12 mo of 
treatment with empagliflozin
Clinical parameter
Empagliflozin-based treatment (n = 20)
Baseline 12 mo P
Weight, kg 90.1 (82.3–101.9) 88.1 (76.2–96.6) 0.003*
BMI, kg/m2 30.5 (26.7–32.7) 29.2 (24.1–31.5) 0.004*
HbA
1c
, mmol/mol 59 (48–66) 52 (42–55) 0.07
Systolic blood pressure, mm Hg 137 (117–147) 130 (125–146) 0.69
Diastolic blood pressure, mm Hg 81 (70–87) 79 (73–82) 0.59
Furosemide dose, mg 20 (0–80) 0 (0–0) 0.02*
Urea, mmol/L 10.7 (8.3–13.2) 9.9 (7.4–13.8) 0.64
Creatinine, μmol/L 129 (98–150) 129 (101–144) 0.82
eGFR, mL/min 48 (43–61) 52 (39–68) 0.97
Data are presented as median (IQR).
*Significant difference between baseline and 12 months.
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA
1c
, glycated hemoglobin; 
IQR, interquartile range.
TABLE 4.
Metabolic and hemodynamic outcomes in heart transplant 
recipients with diabetes mellitus before and after 12 mo of 
treatment with non-empagliflozin-based therapies
Clinical parameter
Non-empagliflozin-based treatment  
(n = 77)
Baseline 12 mo P
Weight, kg 77.1 (69.0–90.5) 77.0 (67.5–88.0) 0.55
BMI, kg/m2 27.2 (24.1–30.7) 27.5 (24.0–31.0) 0.54
HbA
1c
, mmol/mol 52 (42–57) 48 (44–58) 0.13
Systolic blood pressure, mm Hg 132 (122–152) 133 (119–151) 0.99
Diastolic blood pressure, mm Hg 84 (77–90) 81 (74–88) 0.35
Furosemide dose, mg 0 (0–40) 0 (0–40) 0.48
Urea, mmol/L 9.5 (7.2–12.4) 9.6 (7.5–12.0) 0.69
Creatinine, μmol/L 115 (92–142) 119 (103–143) 0.06
eGFR, mL/min 54 (41–74) 52 (42–70) 0.44
Data are presented as median (IQR).
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA
1c
, glycated hemoglobin; 
IQR, interquartile range.
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may have potential to improve outcomes in heart transplant 
recipients with diabetes mellitus as well. The primary out-
come of this study was to examine the safety of empagliflo-
zin in heart transplant recipients with T2DM and/or PTDM. 
Overall, empagliflozin was well tolerated, with only 3 adverse 
effects potentially attributable to treatment. Following 384 
cumulative months of empagliflozin therapy, only 1 patient 
experienced an adverse event, which required permanent dis-
continuation of the drug.
Genitourinary and perineal infections are recognized 
potential adverse effects of treatment with SGLT2 inhibitors. 
Given the immunosuppressed profile of the posttransplant 
patient, there was theoretically increased risk of genitouri-
nary infection with empagliflozin use in this setting. However, 
across 384 cumulative months of treatment, no recorded 
cases of genitourinary infection were documented among 
the 22 patients treated with empagliflozin. We acknowledge 
that antimicrobial prophylaxis is a fundamental component 
of posttransplant care, but the choice of antibiotics is not 
directed at preventing genitourinary infection, so it is unlikely 
that anti-infective prophylaxis mitigated the risk of genito-
urinary infection in heart transplant recipients treated with 
empagliflozin relative to those treated without.
There have been multiple reports of euglycemic diabetic 
ketoacidosis (DKA) occurring in patients receiving SGLT2 
inhibitor therapy.12 Although rare, ketoacidosis is a life-threat-
ening emergency, and it is reassuring that no instances were 
observed in our treated patients. Screening, as in the nontrans-
plant setting, is not routinely performed and requires vigilance 
on the part of treating physicians to consider ketonemia in 
patients with unexplained metabolic acidosis and raised anion 
gap. Ketoacidosis is usually clinically apparent, and given the 
posttransplant patient is closely monitored, we feel it is unlikely 
that cases were missed. However, as screening was not rou-
tinely performed, it is possible that mild cases may have been 
missed, and larger studies are required to establish if DKA risk 
is higher in transplant patients compared with non-transplant 
patients with T2DM, where euglycemic DKA is very rare.
Posttransplantation treatment regimens are complex and 
intricately balanced, as patients require a range of immu-
nosuppressive and anti-infective therapies in addition to 
the management of comorbidities frequently seen in this 
population, such as hypertension and hypercholesterolemia. 
Although there is presently minimal data available regard-
ing the use of SGLT2 inhibitors in transplant patients, a 
pharmacokinetic study did not demonstrate any meaningful 
interaction between canagliflozin and cyclosporine.13 In our 
cohort, there were no apparent drug-drug interactions involv-
ing empagliflozin, although this was not specifically assessed. 
Metabolism of empagliflozin is via simple hepatic glucuro-
nidation and would not be expected to interfere with P450 
or P-glycoprotein pathways via which calcineurin inhibitors 
and mTOR agents are metabolized. From a safety perspective, 
the results of this study suggest that empagliflozin is suitable 
for use in the postcardiac transplant setting. Nonetheless, in 
patients with a history of genitourinary infections or preexist-
ing lower urinary conditions, we would advise caution in the 
use of SGLT2 inhibitors.
The secondary outcome of this study was to examine effi-
cacy of empagliflozin therapy in heart transplant recipients 
with diabetes mellitus. In our studied patient population, 
empagliflozin resulted in significant reductions in body weight 
and BMI that were not observed in patients treated using 
glucose-lowering therapies that did not include empagliflozin. 
Trial data from nontransplant T2DM patients treated with 
empagliflozin have demonstrated significant reductions in 
blood pressure by week 16,5 which was maintained through-
out the study period. In our cohort, empagliflozin did not 
appreciably change systolic or diastolic blood pressures after 
12 months of treatment. This may be an effect of the small 
sample size of our cohort, although interestingly, patients 
treated with empagliflozin were more likely to have ceased 
or to be on a reduced dose of furosemide after 12 months 
of treatment compared with patients not treated with empa-
gliflozin, where no significant changes in blood pressure or 
diuretic use were observed.
We observed a mean reduction in HbA1c of 6.6 mmol/
mol in the empagliflozin group. Although not statistically 
significant, it is clinically relevant given that patients treated 
with other non-empagliflozin-based glucose-lowering treat-
ments on average experienced a mean increase in HbA1c of 
3.7 mmol/mol despite similar degrees of follow-up and endo-
crinology involvement. These data suggest empagliflozin was 
efficacious for improving glycemic control in heart transplant 
patients with diabetes mellitus relative to treatment using 
non-empagliflozin-based diabetes mellitus therapies and is 
consistent with the published data in this area.5,8
The prevalence of chronic kidney disease in the posttrans-
plant setting has been reported as 25%, 51%, and 68% at 1, 5, 
and 10 years, respectively, among surviving recipients.14 This 
is largely due to the modern immunosuppressive regimens and 
widespread use of nephrotoxic calcineurin inhibitors.15 In our 
study, renal function in both empagliflozin and control groups 
remained stable over the 12-month observation period. This is 
in keeping with nontransplant data from a T2DM population, 
where empagliflozin in addition to standard care resulted in 
slower progression of kidney disease and significantly lowered 
the risk of multiple other clinically relevant renal outcomes 
when compared with placebo.16 A longer duration of observa-
tion will be needed to determine whether the SGLT2 inhibi-
tors are also renoprotective in patients with diabetes mellitus 
following heart transplantation.
Strengths of our study are the long-term follow-up (12 
months) of transplant patients treated with a new glucose-
lowering agent (empagliflozin). This builds on our previous 
published data of empagliflozin use in heart transplant recipi-
ents and improves confidence that use is safe and may impart 
significant metabolic benefits in a posttransplant population. 
The most significant limitations of this study relate to its ret-
rospective and nonrandomized design. The decision to com-
mence treatment with empagliflozin was made by the treating 
endocrinologist or cardiologist. Heart transplant recipients 
treated with empagliflozin were also more likely to be treated 
with metformin. The possibility that benefits in terms of 
weight loss and glycemic control may have been related to 
metformin rather than empagliflozin (or the combination of 
the 2) cannot be excluded. Our observations would ideally be 
confirmed in a prospective randomized trial.
CONCLUSIONS
In conclusion, this study has demonstrated that empagli-
flozin can be safely used as a long-term option for the man-
agement of selected patients with diabetes mellitus following 
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heart transplantation. On the basis of our cohort study results, 
we suggest that heart transplantation should not act as an 
absolute contraindication to SGLT2 inhibitor therapy.
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